欧洲中部夏令时间2023年9月28日,欧洲内科肿瘤学会(ESMO)公布了即将召开的2023年ESMO大会上最为重磅的摘要LBAs(Late- Breaking Abstracts)题目及信息,覆盖Presidential Symposium(主席专场)、Proffered Paper Session(优选论文专场)、Mini Oral Session(简短口头报告专场)。
在妇科肿瘤领域,LBAs共计12项,其中,妇瘤专场10项,主席专场2项。【肿瘤资讯】特将摘要信息整理如下,与您同鉴!
优选论文专场——妇瘤1
专场时间:2023年10月20日 16:00-17:30(北京时间:10月20日 22:00-23:30)
专场主席:David SP Tan (Singapore, Singapore),Ana Oaknin (Barcelona, Spain)
专场地点:Sevilla Auditorium - Hall 9
摘要号:LBA36
Senaparib维持治疗新诊断晚期卵巢癌患者的有效性和安全性(FLAMES研究):随机、双盲、安慰剂对照、3期试验
Efficacy and Safety of Senaparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer (FLAMES Study): A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
讲者:吴小华(中国,上海)
摘要号:LBA37
阿替利珠单抗(atezo)联合铂类化疗(CT)和尼拉帕利维持治疗复发性卵巢癌(rOC),无铂间隔(TFIp)>6个月:双盲安慰剂(pbo)控制的ENGOT-Ov41/GEICO 69-O/ANITA 3期试验的初步分析
Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial
讲者:Antonio Gonzalez Martin (Madrid, Spain)
摘要号:LBA38
帕博利珠单抗+放化疗治疗高危局部晚期宫颈癌:一项随机、双盲、3 期ENGOT-CX11/GOG-3047/KEYNOTE-A18 研究
Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
讲者:Domenica Lorusso (Rome, Italy)
摘要号:LBA39
BEATcc(ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030)的主要结果,这是一项一线阿替利珠单抗(atezo)联合铂类双联和贝伐珠单抗(BEV)治疗转移性(IVB期)、持续性或复发性宫颈癌(R/M CC)的随机3期试验
Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
讲者:Ana Oaknin (Barcelona, Spain)
优选论文专场——妇瘤2
专场时间:2023年10月21日 8:45-10:00(北京时间:10月21日 14:45-16:00)
专场主席:Domenica Lorusso (Rome, Italy),Sven Mahner (München, Germany)
专场地点:Bilbao Auditorium - NCC
摘要号:LBA40
阿替利珠单抗联合卡铂和紫杉醇治疗晚期/复发性子宫内膜癌女性的III期双盲随机安慰剂对照试验
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
讲者:Nicoletta Colombo (Milan, Italy)
摘要号:LBA41
度伐利尤单抗(durva)加卡铂/紫杉醇(CP),然后维持(mtx)durva ±奥拉帕利(ola)作为新诊断的晚期或复发性子宫内膜癌(EC)的一线(1L)治疗:III期DUO-E/GOG-3041/ENGOT-EN10试验结果
Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial
讲者:Shannon N. Westin (Houston, United States of America)
摘要号:LBA42
奥拉帕利与安慰剂作为晚期/转移性子宫内膜癌患者铂类化疗后的维持治疗:GINECO 随机 IIb 期UTOLA试验
Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
讲者:Florence Joly Lobbedez (Caen, Cedex 5, France)
简短口头报告专场——妇瘤
专场时间:2023年10月22日 10:15-11:55(北京时间:10月22日 16:15-17:55)
专场主席:Christian Marth (Innsbruck, Austria),Alexandra Leary (Villejuif, France),Kosei Hasegawa (Saitama, Japan)
专场地点:Valencia Auditorium - Hall 10
摘要号:LBA43
NRG GY 018试验中,按错配修复丢失机制列出的,接受帕博利珠单抗联合卡铂/紫杉醇(CP)治疗的子宫内膜癌(EC)患者(pts)与接受CP联合安慰剂(PBO)治疗的患者(pts)的最新缓解数据和无进展生存期分析
Updated Response Data and Analysis of Progression Free Survival by Mechanism of Mismatch Repair Loss in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial
讲者:Ramez N. Eskander (La Jolla, United States of America)
摘要号:LBA44
卡瑞利珠单抗+famitinib与单用卡瑞利珠单抗的比较,以及研究者在复发或转移性宫颈癌女性中的化疗选择
Camrelizumab plus famitinib versus camrelizumab alone and investigator’s choice of chemotherapy in women with recurrent or metastatic cervical cancer
讲者:吴小华(中国,上海)
摘要号:LBA45
NRG-GY004的总生存期(OS)结果,这是一项III期研究,比较单药奥拉帕利或Cediranib和奥拉帕利联合化疗与铂类(Plat)化疗治疗复发性铂敏感卵巢癌(OvCa)
Overall Survival (OS) Outcomes from NRG-GY004, a Phase III Study Comparing Single-Agent Olaparib or Combination Cediranib and Olaparib to Platinum (Plat) Based Chemotherapy in Recurrent Plat Sensitive Ovarian Cancer (OvCa)
讲者:Joyce F. Liu (Boston, United States of America)
优选论文专场——主席专场 2
专场时间:2023年10月22日 16:30-18:15(北京时间:10月22日 22:30-00:15)
专场主席:Andres Cervantes (Valencia, Spain),Silke Gillessen (Bellinzona, Switzerland)
专场地点:Madrid Auditorium - Hall 6
摘要号:LBA8 (北京时间23:10-23:22)
GCIG INTERLACE试验:一项随机III期试验,在局部晚期宫颈癌中,诱导化疗后放化疗与单独放化疗的比较
A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial
讲者:Mary McCormack (London, United Kingdom)
摘要号:LBA9 (北京时间23:22 - 23:34)
InnovaTV 301/ENGOT-cx12/GOG-3057:一项在复发或转移性宫颈癌患者中比较2L或3L Tisotumab Vedotin治疗与研究者选择的化疗的全球、随机化、开放标签、III期研究
innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer
讲者:Ignace B. Vergote (Leuven, Belgium)
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/calendar
排版编辑:肿瘤资讯-Hedy